Re: Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: A prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial)

摘要

De novo urothelial bladder cancer (BCa) occurs in 30-50% of patients following radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) [1], with the majority of tumors occurring in the first postoperative year. It is suspected that this situation is in part related to cell implantations that are derived from the primary tumor. Consequently, implantation may be hampered by early postoperative intravesical instillation of a chemotherapeutic agent such as mitomycin C (MMC).